Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9386639 | 0.88 | KDM4E (0.59) | KDM4EHPGDALDH1A1LMNAHTT | |
| SCHEMBL9079033 | 0.85 | KDM4E (0.56) | KDM4EHPGDALDH1A1LMNAHTT | |
| SCHEMBL8310231 | 0.84 | HPGD (0.68) | KDM4EHPGDALDH1A1LMNAHTT | |
| SCHEMBL3336139 | 0.81 | KDM4E (0.73) | KDM4EHPGDALDH1A1LMNAHTT | |
| SCHEMBL6581763 | 0.81 | KDM4E (0.69) | KDM4EHPGDALDH1A1LMNAHTT | |
| N-Desmethyldofetilide SCHEMBL7853191 | 0.80 | KCNH2 (0.64) | KDM4EHPGDALDH1A1LMNAHTT | |
| Hydrochloric Acid SCHEMBL9445091 | 0.78 | GAA (0.62) | KDM4EHPGDALDH1A1LMNAHTT | |
| SCHEMBL7208101 | 0.78 | PRMT1 (0.62) | ALDH1A1HTTADRB2ADRB1ADRB3 | |
| SCHEMBL7208126 | 0.78 | ADRB2 (0.54) | ALDH1A1HTTSMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL16976564 | 0.78 | KDM4E (0.65) | KDM4EHPGDALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1531811-A2 | DERIVATIVES OF 3-HYDROXY-4-(CYCLYL-ALKYLAMINOALKYL)-5-PHENYL-1H-PYRAZOLE AS ANTAGONISTS OF THE GONADOTROPIN RELEASING HORMONE (GNRH) FOR USE IN THE TREATMENT OF SEX HORMONE RELATED CONDITIONS, SUCH AS PROSTATIC OF UTERINE CANCER | AstraZeneca AB (SE) | 2005-05-25 | — | — | EP | claimed |
| WO-2004017961-A2 | DERIVATIVES OF 3-HYDROXY-4-(CYCLYL-ALKYLAMINOALKYL)-5-PHENYL-1H-PYRAZOLE AS ANTAGONISTS OF THE GONADOTROPIN RELEASING HORMONE (GNRH) FOR USE IN THE TREATMENT OF SEX HORMONE RELATED CONDITIONS, SUCH AS PROSTATIC OF UTERINE CANCER | ASTRAZENECA AB (SE) | 2004-03-04 | — | — | WO | claimed |
| WO-2015153762-A1 | SOTALOL COMPOSITIONS AND USES OF THE SAME | ARBOR PHARMACEUTICALS, LLC (US) | 2015-10-08 | — | — | WO | disclosed |
| US-7514570-B2 | Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (GnRH) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer | ASTRAZENECA AB (SE) | 2009-04-07 | — | — | US | disclosed |
| EP-1531811-B1 | DERIVATIVES OF 3-HYDROXY-4-(CYCLYL-ALKYLAMINOALKYL)-5-PHENYL-1H-PYRAZOLE AS ANTAGONISTS OF THE GONADOTROPIN RELEASING HORMONE (GNRH) FOR USE IN THE TREATMENT OF SEX HORMONE RELATED CONDITIONS, SUCH AS PROSTATIC OF UTERINE CANCER | ASTRAZENECA AB (SE) | 2008-10-29 | — | — | EP | disclosed |
| US-20060287379-A1 | Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | disclosed |
| EP-1531811-A2 | DERIVATIVES OF 3-HYDROXY-4-(CYCLYL-ALKYLAMINOALKYL)-5-PHENYL-1H-PYRAZOLE AS ANTAGONISTS OF THE GONADOTROPIN RELEASING HORMONE (GNRH) FOR USE IN THE TREATMENT OF SEX HORMONE RELATED CONDITIONS, SUCH AS PROSTATIC OF UTERINE CANCER | AstraZeneca AB (SE) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004017961-A2 | DERIVATIVES OF 3-HYDROXY-4-(CYCLYL-ALKYLAMINOALKYL)-5-PHENYL-1H-PYRAZOLE AS ANTAGONISTS OF THE GONADOTROPIN RELEASING HORMONE (GNRH) FOR USE IN THE TREATMENT OF SEX HORMONE RELATED CONDITIONS, SUCH AS PROSTATIC OF UTERINE CANCER | ASTRAZENECA AB (SE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287379-A1 | Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer | GNRHR, LHCGR, GHRHR | KDM4E 963/4885HPGD 334/4885ALDH1A1 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.